Study characteristics: a randomized, double-blind, placebo-controlled, parallel-group, single-center trial with a delayed onset paradigm (Early-start group with 12 months of deferiprone versus delayed -start group with 6 months of placebo then 6 months of deferiprone) to study the effect of deferiprone on the relaxation time of the substantia nigra during a T2* MRI sequence (R2*=1/T2* reflecting iron overload) with respect to motor disorders in Parkinson's disease.